China Biologic Receives SFDA Approval For Clinical Trials Of FVIII
Sep 22nd, 2008 | By Editor | Category: NewsChina Biologic Products, a company producing plasma-based pharmaceuticals, has received approval from the Chinese State Food and Drug Administration to commence clinical trials of its new Human Coagulation Factor VIII product — a coagulation treatment for hemophilia and mass hemorrhaging.
